drugset / Trial / NCT03440424
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will be conducted to assess the effect of mild and moderate hepatic impairment on the pharmacokinetics (PK) of lemborexant after a single-dose administration.
Timeline
- Start
- 2018-01-26
- Primary completion
- 2018-04-23
- Completion
- 2018-04-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lemborexant | Small molecule | 10 mg | Oral |
Indications
No indication recorded.